| Ytd | 20.87% | |
| 1y | -63.38% |
| Open | 0.62 | Prev Close | 0.61 | Low | 0.60 | High | 0.63 | Mkt Cap | 12.19M |
| Vol | 1.10K | Avg Vol | 314.96K | EPS | -1.13 | P/E | -0.54 | Forward P/E | -1.16 |
| Beta | -0.35 | Short Ratio | 2.03 | Inst. Own | 3.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.73 | 200-d Avg | 0.74 | 1yr Est | 8.88 |
LGVN News
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy fo
Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
Poster Presentation (Exhibit Hall) Date:Monday, July 13, 2026Time:7:30am – 4:15pm BSTSession:In-Pers
According to the EMA, SME Designation has allowed for improved success rate for organizations seekin
https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.h
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst con
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLH
The Company intends to submit to the FDA a Sponsor Statistical Analysis Plan (SAP) for ELPIS II with
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy
On Thursday, 369 companies hit new 52-week lows.